Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorPowles, T. B.
dc.contributor.authorChistyakov, V.
dc.contributor.authorBeliakouski, V.
dc.contributor.authorSemenov, A.
dc.contributor.authorEveraert, E.
dc.contributor.authorBaranau, Y.
dc.contributor.authorMoreno, V.
dc.contributor.authorValderrama, B. Perez
dc.contributor.authorVano, Y.
dc.contributor.authorDel Conte, G.
dc.contributor.authorLoriot, Y.
dc.contributor.authorKang, T. W.
dc.contributor.authorTammaro, M.
dc.contributor.authorO'Hagan, A.
dc.contributor.authorHosseini, M.
dc.contributor.authorTriantos, S.
dc.contributor.authorChhabra, H.
dc.contributor.authorSantiago-Walker, A.
dc.contributor.authorSiefker-Radtke, A. O.
dc.contributor.authoraffiliation[Powles, T. B.] Queen Mary Univ London, St Bartholomews Hosp, Expt Canc Med Ctr, Barts Canc Inst,Dept Genitourinary Oncol, London, England
dc.contributor.authoraffiliation[Chistyakov, V.] LLC Novaya Clin, Med Oncol, Pyatigorsk, Russia
dc.contributor.authoraffiliation[Beliakouski, V.] Gomel Reg Clin Oncol Dispensary, Med Oncol, Gomel, Russia
dc.contributor.authoraffiliation[Semenov, A.] Reg Budgetary Healthcare Inst, vanovo Reg Oncol Dispensary, Ivanovo, Russia
dc.contributor.authoraffiliation[Everaert, E.] AZ Nikolaas Hosp, Med Oncol, St Niklaas, Belgium
dc.contributor.authoraffiliation[Baranau, Y.] Minsk City Clin Canc Ctr, Chemotherapy Dept, Minsk, BELARUS
dc.contributor.authoraffiliation[Moreno, V.] Univ Hosp, Fdn Jimenez Diaz, START Madrid FJD, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Valderrama, B. Perez] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Vano, Y.] Univ Paris Descartes Sorbonne Paris Cite, INSERM, UMRS970, Med Oncol, Paris, France
dc.contributor.authoraffiliation[Del Conte, G.] IRCCS, San Raffaele Sci Inst, Dept Oncol, Milan, Italy
dc.contributor.authoraffiliation[Loriot, Y.] Univ Paris Saclay, Univ Paris Sud, Inst Gustave Roussy, Med Oncol, Villejuif, France
dc.contributor.authoraffiliation[Kang, T. W.] Chonnam Natl Univ Med Sch, Urol, Gwangju, South Korea
dc.contributor.authoraffiliation[Santiago-Walker, A.] Janssen Res & Dev, Res & Dev, Spring House, PA USA
dc.contributor.authoraffiliation[Siefker-Radtke, A. O.] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol Dept, Houston, TX USA
dc.contributor.funderJanssen Research & Development, LLC
dc.date.accessioned2025-01-07T15:33:00Z
dc.date.available2025-01-07T15:33:00Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.2103
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.2103
dc.identifier.urihttps://hdl.handle.net/10668/27230
dc.identifier.wosID700527703502
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS1303-S1303
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleErdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía